Results 181 to 190 of about 156,654 (268)

Lighting up Macrophage Reprogramming Assists Immunosuppressive Niche Modulation in Primary Tumors and Tumor‐Draining Lymph Nodes of Breast Cancer

Advanced Science, EarlyView.
This study develops an intelligent NIR‐II‐responsive nanoplatform to combat immunosuppression in breast cancer. It enables real‐time visualization of macrophage activity via “off‐on” fluorescence while simultaneously reprogramming macrophages through the CSF‐1R and CD47‐SIRPα pathways.
Yingbo Li, Di Chang, Jie Yang, Ying Bai, Min Chen, Daoshuang Li, Zuoyu Xu, Jiaxin Yuan, Xiaoxuan Xu, Zhiqi Zhang, Yize Li, Zixin Chen, Jinbing Xie, Zebin Xiao, Shenghong Ju   +14 more
wiley   +1 more source

Toward organ preservation in thoracic malignancies: why interpretable multimodal radiopathomics matters in the neoadjuvant immunotherapy era. [PDF]

J Immunother Cancer
Jiang W, Fan Y, Zhao J, Zeng J, Wu L.
europepmc   +1 more source

Targeting Golgi–STING Signaling to Reprogram Innate and Adaptive Immunity for the Treatment of Implant‐Associated Infections

Advanced Science, EarlyView.
This study presents an ultrasound‐responsive nanoplatform, CS‐BT@MZ@NEs, with a BaTiO3/Mn‐Zif‐8 core and a chondroitin sulfate coating for Golgi targeting. By leveraging neutrophil hitchhiking, it enables targeted delivery to infection sites. Under ultrasound stimulation, CS‐BT@MZ@NEs generates ROS and modulates Golgi pH to activate cGAS–STING ...
Shicheng Huo, Naifeng Zhu, Zhuocheng Lyu, Yifei Liu, Zhenjiang Xu, Chun Zhou, Yaochao Zhao, Changgui Shi   +7 more
wiley   +1 more source

Beyond Biomarkers: Empiric Immunotherapy in Refractory Epilepsy and the Search for Responders. [PDF]

Epilepsy Curr
Lapalme-Remis S.
europepmc   +1 more source

Amplification of Endoplasmic Reticulum Stress via Inhibiting Lipid Droplet Formation to Enhance Chemodynamic Immunotherapy

Advanced Science, EarlyView.
An endoplasmic reticulum (ER)‐targeted chemodynamic nanoagent (TCBQ/iLD‐ER NPs) comprising •OH‐generating tetrachloro‐1,4‐benzoquinone (TCBQ) and lipid droplets (LDs) formation inhibitor (iLD) is developed for chemodynamic immunotherapy of tumors. After ingestion by cancer cells, TCBQ/iLD‐ER NPs preferentially accumulate in the ER and react with ER ...
Huilan Cai, Shaoru Zhuang, Yang Zhu, Rujiang Ao, Meili Yu, Tingting Cui, Jun Wang, Xuegang Niu, Hongwei Huang, Shanshan Peng, Yu He, Lisen Lin, Huanghao Yang   +12 more
wiley   +1 more source

Methodological considerations in the combined methylphenidate and physical activity trial for cancer-related fatigue in immunotherapy patients. [PDF]

Palliat Support Care
Sona D, Pratiwi TI, Nuryono W, Nursalim M.   +3 more
europepmc   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

Advanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, Dong Lu, Xin Luan   +11 more
wiley   +1 more source

IFN-γ PET imaging stratifies and predicts response to CD137 agonism in a syngeneic colorectal tumor model. [PDF]

J Immunother Cancer
Deck AJ, Saliganan AD, Lane S, Jang H, Chen K, Kim S, Viola NT.   +6 more
europepmc   +1 more source

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source